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Poster Session II S313were graft versus host disease (acute/chronic, grade, day of onset,
affected organ), infections, survival, relapse, day of bone marrow re-
generation and immunosuppression therapy.We found a statistically
significant association between rising levels of HLA-G during trans-
plantation and clinically relevant (grade II-IV) acute GvHD, infec-
tious events after transplantation, in particular fungal infections,
and development of chronic GvHD. Our preliminary data shows
that sHLA-G molecules are involved in several complications after
allogeneic hematopoietic cell transplantation.Bronquiolitis Obliterans- Patient Characteristics
CHARACTERISTICS N5 50
age 25 (2 – 50)
Recipient M / Donor F 20(40%)
Donor and recipient match
matched 40 (80%)
Source of stem cell
BM 46 (92%)
other (PB or CB) 4(8%)
Donor
related 45 (90%)
unrelated 5 (10%)
Diagnosis
CML 24 (48%)
AML 8 (16%)
ALL 5 (10%)
Fanconi Anemia 5 (10%)
Others 8 (16%)
Chronic GVHD onset
progressive 19 (38%)
quiescent 19 (38%)
de novo 8 (16%)422
AN IN-VIVO MODEL OF HUMAN T CELL-MEDIATED REJECTION OF ALLO-
GENEIC MISMATCHED HEMATOPOIETIC CD34 + STEM CELLS USING
NOD/SCID GNULL (NOG) MICE
Nicolini, B., Mahmud, D., Mahmud, N., Nucifora, G., Rondelli, D.
University of Illinois at Chicago
Anti-humanCD34+ cell T cell alloreactivity was previously shown
in-vitro. In this study we transplanted human CD34+ cells and allo-
geneic T cells in a NOD/SCID gnull (NOG) mouse model to evalu-
ate the occurrence of stem cell rejection in-vivo. After sublethal
irradiation NOG mice received 2105 CB CD34+ cells and alloge-
neic blood T cells at 1:0 (control), 1:2, or 1:10 CD34+ cell: T cell ra-
tio (n5 5-10 mice per group). Human cell engraftment was assessed
in the bone marrow and in the spleen 6 weeks following transplanta-
tion. Marrow engraftment of huCD45+ cells was 606 10% in con-
trol mice and included B cells (646 4%), CD34+ cells (186 1%),
CD33+ myeloid cells (76 1%), CD14+ monocytes (36 1%). In
contrast, mice that were transplanted with CD34+ cells and low
dose (1:2 ratio) or high dose (1:10 ratio) allo-T cells had only
96 2% and 36 1% huCD45+ cells, respectively, in the bone mar-
row (p5 0.01) and .98% were huCD3 +T cells. Spleen engraft-
ment of huCD45+ cells was lower (256 8%) in control mice (1:0
ratio) as compared to 666 10% and 366 11% in 1:2 and 1:10
groups, respectively (p5 0.05). However, also the spleen of mice re-
ceiving CD34+ and T cells included .98% CD3 +T cells. Among
the T cells, both in the marrow and in the spleen of mice in the
1:2 and 1:10 ratio groups, 60-70% were CD4 +CD8- cells, 22-
25% CD8 +CD4- cells, 1-3% CD56+ cells, and 2-5%
CD4 +CD25+ cells. Only in mice receiving low doses of T cells,
on average 126 6% of the T cells in the bone marrow and spleen
were CD4 + CD8+. Mice receiving high doses of T cells had acute
xenogeneic GVHD demonstrated by fur changes, reduced survival
(p5 0.02) and weight loss (p5 0.0001) compared to control mice
or mice receiving a lower dose of T cells (1:2 ratio). In-vitro mixed
leukocyte cultures with irrad CD34+ cells and allogeneic T cell re-
sponders (R) at the same ratio as in in-vivo experiments were then
performed w/wo the addition of CD4 +CD25+ regulatory T cells
(Tregs) at 1:1 or 1:5 Treg: R ratio. Since a 60% T cell suppression
was observed only with equal numbers of Tregs and allo-responders,
we are currently testing whether auto or allo Tregsmay prevent stem
cell rejection in NOG mice transplanted with CD34+ cells, alloge-
neic T cells and Tregs at 1:2:2 or 1:1:2 ratio. NOG mice represent
a useful model to study human T cell mediated bone marrow failure
or stem cell rejection and will allow us to investigate new strategies of
allogeneic transplantation with subsets of T cells or hematopoietic
stem cells.after DLI 3 (6%)
Risk characteristics
platelets less than 100.000/mm3 21 (42%)
.3 organs 27 (54%)
\1500 lymphocytes 39 (78%)
NIH global scoring
Moderate 14 (28%)
Severe 36 (72%)423
BRONCHIOLITIS OBLITERANS AFTER ALLOGENEIC STEM CELL TRANS-
PLANTATION – AN ANALYSIS OF 50 CASES OVER THIRTY YEARS AT A SIN-
GLE BRAZILIAN INSTITUTION
Vieira, A.G., Funke, V.A.M., Nunes, E.C., Setubal, D.C., Medeiros, L.,
Michels, M., Ribeiro, L., Morando, J., Bonamin, C., Nabhan, S.,
Bitencourt, M.A., Bonfim, C., Loth, G., Franco, V., Pasquini, R.,
Neto, J.Z. Hospital de Clinicas Federal University of Parana, Curitiba,
Parana, BrazilIntroduction: Bronchiolitis obliterans (BO) is a late complication of
hematopoietic stem cell transplantation (HSCT) usually associated
with chronic graft versus host disease (C-GVHD) and often fatal.
We describe here characteristics and clinical course of 50 patientsat a brazilian transplant center who developed bronchiolitis obliter-
ans as a manifestation of chronic graft versus host disease.
Patients andMethods:We searched the database and reviewed the
medical records of 1645 patients who received HSCT between 1979
and 2009, and identified 50 patients who developed BO, whose clin-
ical features and clinical course were analyzed retrospectively. The
diagnosis of BOwas determined by either the presence of an obstruc-
tive ventilatory defect on a pulmonary function test or a chest CT
showing small airways wall thickening or air trapping associated
with a typical clinical picture in the context of a patient with C-
GVHD. NIH criteria were used to define the severity of C-GVHD.
Results:TheprevalenceofBOin these30yearswas 3%.Patient char-
acteristics are summarized inTable 1.According to the severity of pul-
monary involvement 14 patients (28%) had score 1, 12 (24%) had
score 2, and 22 (44%) had score 3. Median time between transplanta-
tion and diagnosis ofC-GVHDwas 138 days (33-3738), whilemedian
time between the diagnosis of C-GVHD and the diagnosis of BOwas
77days (0 –1752).Median timebetween transplantationanddiagnosis
of BOwas 343 days (38 – 3877). Twenty-nine patients (58%) required
second-line treatment due to lack of response. The main secondary
treatments used were: thalidomide(11); azathioprine(18), tacrolimus
(7); mycophenolatemofetil (7) and photopheresis (1).Median survival
for this group was 1637 days (195 – 6102). At the time of this analysis
23 (46%) patients had died from BO related causes.
Conclusion: Bronchiolitis obliterans was a serious late complica-
tion, occurring in 3% of patients transplanted in our center over
the past 30 years. Mortality rate was high (46%) and most patients
(58%) did not respond to primary therapy. Better understanding of
the pathophysiology of C-GVHD is necessary for the development
of more effective therapeutic tools.424
PKCQ IS REQUIRED FOR ALLOREACTIVITY AND GVHD BUT NOT FOR
IMMUNE RESPONSES TOWARD LEUKEMIA AND INFECTION IN MICE
Yu, X.-Z.1, Valenzuela, J.O.1, Iclozan, C.A.1, Blazar, B.R.2,
Waller, E.K.3, Beg, A.A.1 1Moffitt Cancer Center, Tampa, FL; 2Univer-
sity of Minnesota, Minneapolis, MN; 3Emory University School of Medi-
cine, Atlanta, GA
